A New Bowel Cancer Treatment Just Erased Tumors For Years

Imagine a cancer treatment that doesn't just shrink tumors, but makes them vanish. Then, for almost three years, they just… stay gone. That's the reality for patients in a new trial for a specific type of bowel cancer, who received a short course of immunotherapy before surgery, rather than the usual chemotherapy afterward.

These findings, hot off the presses from the NEOPRISM-CRC clinical trial led by UCL and UCLH researchers, are making waves. They build on earlier data that showed a nine-week immunotherapy treatment called pembrolizumab dramatically reduced tumor size in patients with stage two or three bowel cancer. Early results were promising, with 59% of patients showing no detectable cancer after treatment and surgery. The latest update? After 33 months, none of those patients have seen their cancer return. Let that satisfying number sink in.

Normally, about a quarter of patients who go through surgery and chemo will see their cancer make an unwelcome comeback within three years. This new approach flips that script, suggesting a more enduring defense against the disease. Which, if you think about it, is both impressive and slightly terrifying for the old way of doing things.

Researchers weren't just happy with the results; they wanted to know why it worked. So, they dove into blood samples, creating special tests that can spot early signs of treatment success and even check for lingering cancer cells. The goal? To predict who will benefit most, allowing doctors to tailor treatments – less for those doing great, more for those who need it.

Dr. Kai-Keen Shiu, the trial's chief investigator, is understandably excited. He confirmed pembrolizumab is safe and effective for high-risk bowel cancers, and the ability to predict responses with personalized blood tests and immune profiling is a game-changer. Customizing treatment means less unnecessary hardship for patients.

The Cancer That Vanished

Bowel cancer is the UK's fourth most common cancer, with around 44,000 new cases annually. While it often targets an older demographic, diagnoses in the under-50 crowd are on the rise. Survival rates depend heavily on early detection: 90% for stage one, dropping to 65% for stage three, and a grim 10% for stage four. This trial focused on 32 patients with a specific genetic profile (MMR deficient/MSI-high bowel cancer), which accounts for 10-15% of cases – roughly 2,000-3,000 diagnoses each year in the UK.

Instead of the standard three to six months of post-surgery chemotherapy, these patients received up to nine weeks of pembrolizumab before their operation. Then, they were simply monitored. Professor Marnix Jansen, who leads the trial's research, noted these long-lasting effects are proving consistent, offering crucial insights into why immunotherapy works so well in this context.

Yanrong Jiang, a clinical PhD student, highlighted the power of those personalized blood tests. If tumor DNA vanished from the blood, patients were far more likely to be cancer-free. It was a crystal ball that actually worked.

Christopher's Story

Christopher Burston, 73, from Portland, Dorset, received his bowel cancer diagnosis in February 2023 after a routine screening kit flagged something. A colonoscopy confirmed a substantial lump – stage three cancer. His oncologist suggested the NEOPRISM trial, and despite the travel to London, Christopher jumped in.

He received three doses of immunotherapy over nine weeks, followed by surgery in May 2023. Side effects were minimal, and he recovered quickly. His doctor's assessment post-surgery? The cancer had "melted away." Almost three years later, Christopher remains cancer-free, back to his normal life, and attending regular follow-ups. He feels, as he put it, "very lucky" that his main problem now is age, not illness.

It’s a powerful reminder that sometimes, the best defense is a good offense, especially when it involves turning the body's own immune system into a cancer-fighting superhero. And for patients like Christopher, it means getting back to worrying about the usual aches and pains, not the terrifying ones.